XML 70 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Adjusted EBITDA [1] $ (12,748) $ (28,180)
Share-based compensation expense [2] (12,147) (14,298)
Restructuring expense [3]   $ (1,044)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag   Restructuring expense
Depreciation and amortization expense (4,731) $ (5,214)
Interest expense [4] (2,905) (2,993)
Interest and other income, net 2,679 4,222
Net loss attributable to Adaptive Biotechnologies Corporation (29,852) (47,507)
Net loss attributable to noncontrolling interest 22 (26)
Net loss (29,830) (47,533)
Operating Segments | MRD    
Segment Reporting Information [Line Items]    
Adjusted EBITDA [1] (4,111) (17,259)
Share-based compensation expense [2] (5,464) (6,833)
Restructuring expense [3]   $ (467)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag   Restructuring expense
Depreciation and amortization expense (2,663) $ (2,701)
Operating Segments | Immune Medicine    
Segment Reporting Information [Line Items]    
Adjusted EBITDA [1] (5,446) (6,927)
Share-based compensation expense [2] (4,393) (5,007)
Restructuring expense [3]   $ (577)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag   Restructuring expense
Depreciation and amortization expense (1,642) $ (2,082)
Unallocated Corporate    
Segment Reporting Information [Line Items]    
Adjusted EBITDA [1] (3,191) (3,994)
Share-based compensation expense [2] (2,290) (2,458)
Depreciation and amortization expense (426) (431)
Interest expense [4] (2,905) (2,993)
Interest and other income, net $ 2,679 $ 4,222
[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[2] Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.
[3] Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructuring for details on our restructuring expense.
[4] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.